A Phase 1 Study of TPI 287 Concurrent With Fractionated Stereotactic Radiotherapy (FSRT) in Treatment of Brain Metastases From Advanced Breast and Non-Small Cell Lung (NSCL) Cancer.

Trial Profile

A Phase 1 Study of TPI 287 Concurrent With Fractionated Stereotactic Radiotherapy (FSRT) in Treatment of Brain Metastases From Advanced Breast and Non-Small Cell Lung (NSCL) Cancer.

Recruiting
Phase of Trial: Phase I

Latest Information Update: 02 May 2017

At a glance

  • Drugs TPI 287 (Primary)
  • Indications Brain metastases
  • Focus Adverse reactions
  • Most Recent Events

    • 20 Nov 2015 Results published in a Cortice Biosciences media release.
    • 09 Nov 2015 Results from this trial will be presented at the 20th Annual Society for Neuro-Oncology Annual Scientific Meeting and Education Day according to a Cortice Biosciences media release.
    • 29 May 2015 According to an abstract presented at 51st Annual Meeting of the American Society of Clinical Oncology 2 patients have been enrolled till date.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top